Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic?

BMJ 2001; 322 doi: 10.1136/bmj.322.7292.989 (Published 21 April 2001)
Cite this as: BMJ 2001;322:989

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL